Schikan Johannes Gerardus Christiaan Petrus 4
4 · Pharvaris N.V. · Filed May 1, 2026
Research Summary
AI-generated summary of this filing
Pharvaris (PHVS) Director Johannes Schikan Sells 32,900 Shares
What Happened
Schikan Johannes Gerardus Christiaan Petrus (listed in the filing), a director of Pharvaris N.V. (PHVS), sold a total of 32,900 shares in open‑market transactions on April 29–30, 2026, generating roughly $996,545 in proceeds. The sales broke down as: 3,830 shares @ $30.07 (Apr 29; $115,165), 28,400 shares @ $30.30 (Apr 30; $860,588), and 670 shares @ $31.03 (Apr 30; $20,792). These were sales (not purchases) executed under a Rule 10b5‑1 trading plan, which is typically a pre‑scheduled arrangement.
Key Details
- Transaction dates and reported prices/values:
- 2026-04-29: 3,830 shares sold @ $30.07 — $115,165
- 2026-04-30: 28,400 shares sold @ $30.30 — $860,588
- 2026-04-30: 670 shares sold @ $31.03 — $20,792
- Total shares sold: 32,900; total proceeds ≈ $996,545.
- Shares owned after the transactions: not specified in the provided excerpt of the filing.
- Footnotes: transactions were made pursuant to a scheduled Rule 10b5‑1 trading plan (F1). Footnotes F2–F4 state reported prices are weighted averages for multiple sales on the dates, note that some shares were acquired upon RSU vesting, and provide price ranges for the underlying trades; the filer will provide a per‑price breakdown on request.
- Filing date: May 1, 2026 (transactions dated Apr 29–30, 2026). This filing appears to be within the standard 2‑business‑day window for Form 4 reports.
Context
Sales executed under a 10b5‑1 plan are pre‑arranged and often indicate routine, scheduled disposition rather than a manager’s ad‑hoc view of the company. The filing also notes that some of the shares sold included shares received from restricted stock unit vesting; weighted‑average prices and per‑trade price details are available from the filer upon request.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-04-29$30.07/sh−3,830$115,165→ 384,237 total - Sale
Common Stock
[F1][F3]2026-04-30$30.30/sh−28,400$860,588→ 355,837 total - Sale
Common Stock
[F1][F4]2026-04-30$31.03/sh−670$20,792→ 355,167 total
Footnotes (4)
- [F1]This is a scheduled sale from 10b5-1 trading plan.
- [F2]The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.18. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F3]The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.99. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- [F4]The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $31.03 to $31.05. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.